Margaret Hagan, MD
Infectious Disease · Wichita, KSNPI 1114922887
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among infectious disease clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$683
- Merck$507
- AbbVie$487
- Melinta Therapeutics, LLC$369
- Takeda Pharmaceuticals U.S.A., Inc.$257
- Hospira, Inc.$167
- plus $2K from 24 others
Across 7 payments — averaging $14,973 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$105K
What the payments were for
- Consulting fees$160%
- Food & beverage$4,09699%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 47 | $683 |
| Merck | 32 | $507 |
| AbbVie(2 entities) | 31 | $487 |
| Melinta Therapeutics, LLC | 24 | $369 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $257 |
| Hospira, Inc. | 10 | $167 |
| Paratek Pharmaceuticals, Inc. | 10 | $157 |
| Gilead | 8 | $147 |
| Shionogi Inc | 8 | $144 |
| Octapharma USA, Inc. | 7 | $143 |
| Aimmune Therapeutics, Inc. | 5 | $131 |
| Smith+Nephew | 3 | $128 |
| CSL Behring | 6 | $103 |
| Pfizer | 4 | $86 |
| Ferring Pharmaceuticals Inc. | 4 | $78 |
| Viiv Healthcare Company | 4 | $78 |
| Shire North American Group Inc | 4 | $63 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $62 |
| Grifols USA, LLC | 3 | $59 |
| Astellas Pharma US Inc | 3 | $45 |
| ADMA Biomanufacturing LLC | 2 | $36 |
| AstraZeneca | 2 | $31 |
| Davol Inc. | 1 | $26 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Convatec Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
How this compares
$4,121 in reported general payments places this provider in the 90th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 49 | $27,189 |
| ErtapenemErtapenem Sodium | 21 | $10,183 |
| Cefepime Hcl | 28 | $6,095 |
| Vancomycin Hcl | 35 | $3,018 |
| Meropenem | 15 | $2,488 |
| Itraconazole | 24 | $2,457 |
| CeftriaxoneCeftriaxone Sodium | 46 | $2,190 |
| Cephalexin | 165 | $2,053 |
| Methenamine Mandelate | 12 | $1,940 |
| Doxycycline Hyclate | 61 | $1,261 |
| Methenamine Hippurate | 17 | $1,227 |
| Minocycline Hcl | 29 | $1,042 |
| Ciprofloxacin Hcl | 37 | $661 |
| Cefdinir | 17 | $547 |
| Gentamicin Sulfate | 18 | $256 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Wichita
- Thomas MooreWichita$37K
- Maha AssiWichita$9K
- Garret SeilerWichita$2K
- Keck HartmanWichita$2K
- Jerry PeterieWichita$2K
- Shelley JonesWichita$2K
- Wissam El AtrouniKansas City$15K
- John FriedOverland Park$7K
- Marjorie WongskhaluangLeawood$5K
- Apoorv KalraOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.